Baylor University Medical Center

Physicians Realty Trust Reports Fourth Quarter and Year Ended 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
REIT, Other Health, Hospitals, Health, Construction & Property, Certification, FFO, OMF, Investment, Growth, Baylor University Medical Center, Foot, ESG, CSP, Trustee, Public expenditure, Normalization, Funds from operations, Abrazo Community Health Network, Depreciation, Partnership

Physicians Realty Trust (NYSE: DOC) (the “Company,” the “Trust,” “we,” “our” and “us”), a self-managed health care real estate investment trust, today announced results for the fourth quarter ended December 31, 2023.

Key Points: 
  • Physicians Realty Trust (NYSE: DOC) (the “Company,” the “Trust,” “we,” “our” and “us”), a self-managed health care real estate investment trust, today announced results for the fourth quarter ended December 31, 2023.
  • Total revenue for the fourth quarter ended December 31, 2023, was $135.5 million, an increase of 2.2% from the fourth quarter ended December 31, 2022.
  • Total expenses for the fourth quarter 2023 were $128.2 million, compared to total expenses of $120.3 million for the fourth quarter 2022.
  • Net income for the fourth quarter 2023 was $7.1 million, compared to net income of $11.9 million for the fourth quarter 2022.

Medical Spa Show 2024 Presents Educational Opportunities Featuring an Array of Medical Aesthetics Superstars

Retrieved on: 
Thursday, March 7, 2024
FACS, BSN, Day, Kansas City University, MD, Individual, Physician, Baylor University Medical Center, Next, MSS, Wynn Las Vegas, Keynote, Practitioner, Breast, Face, University, Stick, Nursing, Happiness, Anatomy, Trauma, UCLA, Baylor University

CHICAGO, March 7, 2024 /PRNewswire-PRWeb/ -- The Medical Spa Show, presented by the American Med Spa Association (AmSpa), is the premier trade show for medical spas and non-invasive medical aesthetics, and it will take place from April 11 – 14, 2024, at Wynn Las Vegas. General registration for the event is open now through April 9, 2024—visit http://www.medicalspashow.com/register to register today.

Key Points: 
  • CHICAGO, March 7, 2024 /PRNewswire-PRWeb/ -- The Medical Spa Show, presented by the American Med Spa Association (AmSpa), is the premier trade show for medical spas and non-invasive medical aesthetics, and it will take place from April 11 – 14, 2024, at Wynn Las Vegas.
  • Some of the industry luminaries who will be appearing at Medical Spa Show 2024 include:
    Cary Deuber, CRNFA, CANS (Keynote Speaker): Cary Deuber, CRNFA, CANS, attended Baylor University, where she earned her BSN.
  • She went straight to work at Baylor University Medical Center in Dallas, where she initially settled into vascular and trauma surgery.
  • These medical aesthetics all-stars will also be appearing at MSS 2024:

Dallas Dermatology Partners Named Among D Magazine's 2023 Best Doctors

Retrieved on: 
Wednesday, February 21, 2024
University of Texas System, Private practice, Skin cancer, Psoriasis, Acne, Multimedia, Moses Austin, D Magazine, Education, University, Physician, Steven Naifeh, Baylor University Medical Center, Alpha Omega Alpha, Rosacea, Patient, Saint Louis University, Baylor College of Medicine, Stanford University, Alpha and Omega, American Academy, Research, Nursing

DALLAS, Feb. 21, 2024 /PRNewswire/ -- Dallas Dermatology Partners proudly recognizes all five partners for being peer-selected among D Magazine's best dermatologists in Dallas for 2023.

Key Points: 
  • DALLAS, Feb. 21, 2024 /PRNewswire/ -- Dallas Dermatology Partners proudly recognizes all five partners for being peer-selected among D Magazine's best dermatologists in Dallas for 2023.
  • The final list is selected by their peers, who are other practicing physicians in Dallas, and represents the most "esteemed, exceptionally skilled, and compassionate" Dallas doctors.
  • Meet the Dallas Dermatology Partners included on this year's roster.
  • Dr. Melissa Costner holds the distinction among Dallas Dermatology Partners as the doctor with the longest record— 19 years — of being named among the area's "Best Doctors" list.

World Renowned Cancer Researchers From Spain and U.S. Join Forces to Address Critical Needs and Challenges in Women’s Cancer Research

Retrieved on: 
Thursday, December 7, 2023
Research, Entrepreneur, Philanthropy, Oncology, Consumer, Catalog, Cosmetics, Retail, Foundation, Science, Women, Health, Woman, Organization, Incidence, Breast cancer, Chair, Hospital, Teaching hospital, Patient, Multimedia, Skin care, Prognosis, Cancer, Courtesy, Baylor University Medical Center, Frustration, TNBC, Pharmaceutical industry, Dietary supplement, Medical device

Both lead their own research teams in their respective home countries focused on investigating the rare and aggressive form of cancer in women: triple negative metastatic breast cancer (TNBC).

Key Points: 
  • Both lead their own research teams in their respective home countries focused on investigating the rare and aggressive form of cancer in women: triple negative metastatic breast cancer (TNBC).
  • Dr. O'Shaughnessy added, “In 1985, we were terribly frustrated by the lack of therapeutic options for women with cancer.
  • Mary Kay is at the forefront of women's cancer research, supporting groundbreaking research led by women for women.
  • Mary Kay is committed to helping researchers around the world by supporting translational research (research that links laboratory research directly to the patient), clinical trials aimed at improving the detection, prognosis, and treatment of women's cancers, as well as organizations that support cancer research, such as the FERO Foundation in Spain.

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

Retrieved on: 
Sunday, October 22, 2023
Gastroenterology, FDA, Comorbidity, Hepatorenal syndrome, American College, Respiratory failure, PDT, EDT, Heart rate, Boxed warning, Oxygen saturation (medicine), Use, DBP, Physician, ACG, Cirrhosis, Mortality, Effect, Treatment, Post hoc analysis, MAP, SBP, Acute kidney injury, American College of Gastroenterology, Research, ACLF, Baylor University Medical Center, Phase, White, Chronic liver disease, Risk, Hospital, Maryland School, Volume overload, University, Stanford University School of Medicine, CLD, Blood pressure, HRS, Hypoxia, Pharmaceutical industry, Dietary supplement, Medical device, Nursing, Communications satellite, Mallinckrodt, Patient, MD, Terlipressin

DUBLIN, Oct. 22, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three posters detailing findings from Mallinckrodt's latest clinical and health economics outcomes research with TERLIVAZ® (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1,2,3,4 will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Vancouver, British Columbia, taking place October 20-25, 2023.

Key Points: 
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economic outcomes may not be solely attributable to TERLIVAZ.
  • TERLIVAZ® is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.
  • For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks.
  • If TERLIVAZ is used during pregnancy, the patient should be informed of the potential risk to the fetus.

CONAM Multifamily Partners Fund III Purchases Arise Craig Ranch in McKinney, Texas

Retrieved on: 
Wednesday, October 4, 2023
Interior Design, Other Construction & Property, Residential Building & Real Estate, Construction & Property, Urban Planning, REIT, Landscape, Energy Star, Texas Health Resources, Lighting, Partnership, US-75, Dallas North Tollway, Craig Ranch, Southwest Airlines, Multimedia, Development, Walking, University of Texas Southwestern Medical Center, MSA, Restaurant, Baylor University Medical Center, Granite Park Chalet, Methodist Dallas Medical Center, Legacy, Balboa Park, Maple, Stonebriar Centre, HCA Healthcare, Legacy West, Chinese Americans in Dallas–Fort Worth, Shop, Tourism, Southwestern Medical District

CONAM Multifamily Partners Fund III, a discretionary fund sponsored by The CONAM Group (CONAM), is pleased to announce the purchase of Arise Craig Ranch , a 270-unit Class A multi-family community in McKinney, Texas, one of Dallas’ fastest-growing northern suburbs.

Key Points: 
  • CONAM Multifamily Partners Fund III, a discretionary fund sponsored by The CONAM Group (CONAM), is pleased to announce the purchase of Arise Craig Ranch , a 270-unit Class A multi-family community in McKinney, Texas, one of Dallas’ fastest-growing northern suburbs.
  • View the full release here: https://www.businesswire.com/news/home/20231004139108/en/
    Courtesy of The CONAM Group (CONAM) - Arise Craig Ranch is a 270-unit Class A multi-family community in McKinney, Texas, one of Dallas’ fastest-growing northern suburbs.
  • We are very pleased with the additions of Arise Craig Ranch and ALMA On Maple as they close out CONAM’s investment activity for Fund III,” says Jack Cleary, CONAM’s Southeast Acquisitions Director.
  • Situated 30 miles south of Arise Craig Ranch, ALMA On Maple joins the CONAM portfolio after the closing of this asset for a long-term partner.

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

Retrieved on: 
Monday, August 7, 2023
Protalix BioTherapeutics, Medsafe, European Medicines Agency, Tax, MD, Patient, European, Fabry disease, BLA, NYSE, Calendar, Gout, Half-life, Pharmacokinetics, Research, EMA, Russell, FIH, Growth, FDA, PEGylation, Biologics license application, Safety, Civil service commission, Health, Baylor University Medical Center, Israel Innovation Authority, FASN, Webcast, MAA, HDEC, European Commission, KOL, Clinical trial, EDT, Marketing, ERT, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry, Drug, Life insurance, Online shopping, EU, Fabry, Chiesi Farmaceutici

CARMIEL, Israel, Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

Key Points: 
  • "2023 has been a transformational year for Protalix thus far," said Dror Bashan, Protalix's President and Chief Executive Officer.
  • On May 5, 2023, the European Commission (EC) granted marketing authorization to Elfabrio (pegunigalsidase alfa) in the European Union.
  • On June 26, 2023, the Company was included in the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution.
  • Financial expenses, net were $0.8 million for the three months ended June 30, 2023, compared to financial income, net of $0.2 million for the three months ended June 30, 2022.

Dallas Attorney Kyle Pugh Wins $26.5 Million Judgment for Man Paralyzed in Postal Truck Accident

Retrieved on: 
Wednesday, July 26, 2023
Tetraplegia, Surgeon, United States Postal Service, Baylor University Medical Center, Ankylosing spondylitis, Spine, Judgement, Hon, Crash, Walking, District court, Fracture, Law, Douglas v. U.S. District Court ex rel Talk America, Family, Personal injury, Rain, Nightclub

Postal Service worker, delivering mail in the rain on a residential street, could not fit a parcel into a community mailbox.

Key Points: 
  • Postal Service worker, delivering mail in the rain on a residential street, could not fit a parcel into a community mailbox.
  • Mr.
  • Mr.
  • Dallas' Kyle Pugh represents individuals and their families in serious personal injury and wrongful death cases.

Aldous\Walker Trial Win Named Top Medical Malpractice Verdict in Texas for 2022

Retrieved on: 
Wednesday, July 5, 2023
Texas Civil Rights Project, Oxygen, The National Law Journal, Leg, Research, Brain damage, Brain, Frank Andrews (Texas lawyer), Anesthesia, ALM, ALM (company), Patient, Baylor University Medical Center, Civil and political rights, Woman, Pharmaceutical industry

DALLAS, July 5, 2023 /PRNewswire/ -- In this year's listing of top verdicts, Texas Lawyer magazine names a $21 million verdict in an Aldous\Walker LLP case as the largest medical malpractice courtroom win in the state in 2022.

Key Points: 
  • DALLAS, July 5, 2023 /PRNewswire/ -- In this year's listing of top verdicts, Texas Lawyer magazine names a $21 million verdict in an Aldous\Walker LLP case as the largest medical malpractice courtroom win in the state in 2022.
  • ALM's Texas Lawyer, which publishes the list every year, then ranks each verdict overall and by category.
  • The October 2022 verdict was the largest medical malpractice claim and the 20th largest in Texas overall.
  • The full list of top verdicts can be viewed in Texas Lawyer's special report Top Verdicts & Settlements of 2022.

Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

Retrieved on: 
Thursday, June 8, 2023
Breakfast, KOL, Protalix BioTherapeutics, EDT, Baylor University Medical Center, Patient, FASN, Fabry disease, FDA, NYSE, Chiesi Farmaceutici

CARMIEL, Israel, June 8, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced it will host an in-person KOL breakfast in New York on Tuesday, June 27, 2023 at 8:00 a.m. Eastern Daylight Time (EDT), with presentations beginning at 8:30 a.m. EDT.

Key Points: 
  • The event will feature a discussion of the recent approval by the U.S. Food and Drug Administration (FDA) of Elfabrio (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.
  • Ankit Mehta, M.D., FASN (Baylor University Medical Center) will discuss the opportunity for Elfabrio to address the unmet needs in Fabry disease; Giacomo Chiesi, Head of Chiesi Global Rare Diseases, the Company's commercial partner, will discuss Chiesi's commercial capabilities; and the Company's leadership will provide insight into the Company's strategy and future plans.
  • A live question and answer session will follow the presentations.
  • Registration for the event is available at https://lifescievents.com/event/protalix/ , or by clicking here .